Document:

<PAGE>
EXHIBIT 10.1

                         EXECUTIVE EMPLOYMENT AGREEMENT

         This Employment Agreement ("Agreement") is entered into by and between
AcuNetx, Inc. ("Company"), a Nevada corporation, and Ronald A. Waldorf
("Executive") (collectively, "Parties"), effective as of December 23, 2005
("Effective Date").

                                   WITNESSETH

         WHEREAS, the Company desires to employ Executive, to assure itself of
the continued services of Executive; and to have the Executive provide "best
efforts" to support the growth and operations of the Company.

         WHEREAS, Executive desires to be employed by the Company under the
terms and conditions herein.

         NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:

         1. EMPLOYMENT BY THE COMPANY. The Company hereby employs Executive to
render exclusive and full-time services to the Company as President of its Eye
Dynamics Division pursuant to the terms and conditions of this Agreement.
Executive will report directly to the Chief Executive Officer. Executive will
have the responsibilities, duties and authorities that are customarily
associated with such positions. The Executive's supervisor or the Board of
Directors may modify Executive's duties and objectives at its discretion from
time to time.

         2. COMPENSATION. The Company agrees to pay Executive compensation
including base salary, and bonuses, if any, as set forth in this Section 2
below.

                  2.1 SALARY. Executive's monthly base salary will be $12,500
(an annualized rate of $150,000) payable at such times as the Company's payroll
obligations are normally paid.

                  Executive's base salary shall be automatically increased on
each anniversary of the date of this Agreement by the Adjustment Percentage (as
defined below) of the base salary applicable to the previous. As used herein,
"Adjustment Percentage" means the percentage increase, if any, in the Consumer
Price Index for Urban Wage Earners and Clerical Workers (Los Angeles-Long
Beach-Anaheim), as published by the Bureau of Labor Statistics of the U.S.
Department of Labor, over the preceding twelve (12) months.

<PAGE>

         In addition, Executive's salary will be reviewed annually by the
Compensation Committee of the Board. The Compensation Committee shall advise the
Board of its review and make recommendations concerning Executive's ongoing
compensation for the consideration of the entire Board, it being contemplated
that increases in Executive's salary will generally keep pace with increases in
the salaries of other executive officers of the Company.

                  2.2 BENEFITS. The Company also agrees to provide Executive
with benefits consistent with Company policy and practice for its Executives.
The Compensation Committee of the Board will establish an Executive Benefit
Plan, consistent with the financial circumstances of the Company. Such benefits
may include health, life and disability insurance, 401(k) plans, etc.

                  2.3 EXPENSES. Executive is authorized to incur reasonable
expenses for promoting the business of the Company, including expenses for
entertainment, travel and similar items. The Company shall reimburse Executive
for all such expenses on the presentation by Executive of itemized accounts of
such expenditures in accordance with guidelines set forth by the Internal
Revenue Service.

                  2.4 EQUITY INCENTIVE. Executive will be granted 1.3 million
shares of Common Stock (the "Bonus Shares") as a stock bonus, which will vest at
the rate of 33% per year on each anniversary of the date of this Agreement.

                  2.5 TERMINATION. In the event of a change of control, whether
through merger, acquisition, or hostile takeover, all of the Bonus Shares shall
immediately vest. Further, the Bonus Shares will be subject to the following:

                  a. If Executive's employment is terminated by the Company
other than "for Cause" as defined herein, then all of the Bonus Shares shall
vest immediately.

                  b. If Executive's employment by the Company is terminated by
the Company "for Cause" as defined in this Agreement, or if Executive
voluntarily terminates his employment, then all unvested Bonus Shares shall be
cancelled

         3. NON-COMPETITION AND CONFIDENTIALITY.

                  a. NON-COMPETITION. The Company and Executive acknowledge and
agree that Executive's services are of a special and unusual character which
have a unique value to the Company, the loss of which cannot be adequately
compensated by damages in an action at law and if used in competition with the
Company, could cause serious harm to the Company. Accordingly, Executive agrees
that during the term of this Agreement and for a period of 12 months after the
termination of this employment by the Company, irrespective of the reason for
such termination, Executive will not (1) enter into any agreement with or

                                       2
<PAGE>

directly or indirectly solicit or attempt to solicit any employee or other
representatives of the Company (the "Company") for the purpose of causing them
to leave the Company to take employment with any other business entity, or (2)
compete, directly or indirectly, with the Company in any way and that Executive
will not act as an officer, director, employee, consultant, shareholder, lender
or agent of any entity engaged in any business of the same nature as, or in
competition with, the business in which the Company is now engaged, was engaged
during Executive's employment or is engaged at the time of Executive's
termination of employment, except for the ownership of less than five percent
(5%) of the outstanding capital stock of a publicly traded company.

                  b. CONFIDENTIALITY.

                           (1) Executive acknowledges that in Executive's
employment hereunder, Executive will be making use of, acquiring and adding to
the Company's trade secrets and its confidential and proprietary information of
a special and unique nature and value relating to such matters as, but not
limited to, the Company's business operations, internal structure, financial
affairs, programs, software systems, procedures, manuals, confidential reports,
lists of clients and prospective clients and sales and marketing methods, as
well as the amount, nature and type of services, equipment and methods used and
preferred by the Company's clients and the fees paid by such clients, all of
which shall be deemed to be confidential information. Executive acknowledges
that such confidential information has been and will continue to be of central
importance to the business of the Company and that disclosure of it to or its
use by others could cause substantial loss to the Company. In consideration of
employment by the Company, Executive agrees that during the Initial Term and any
renewal term of this Agreement and upon and after leaving the employ of the
Company for any reason whatsoever, Executive shall not, for any purpose
whatsoever, directly or indirectly, divulge or disclose to any person or entity
any of such confidential information which was obtained by Executive as a result
of the Executive's employment with the Company or any trade secrets of the
Company, but shall hold all of the same confidential and inviolate.

                           (2) All contracts, agreements, financial books,
records, instruments and documents; client lists; memoranda; data; reports;
programs; software, tapes; Rolodexes; telephone and address books; letters;
research; card decks; listings; programming; and any other instruments, records
or documents relating or pertaining to clients serviced by the Company or
Executive, the services rendered by Executive, or the business of the Company
(collectively, the "Records") shall at all times be and remain the property of
the Company. Upon termination of this Agreement and Executive's employment under
this Agreement for any reason whatsoever, Executive shall return to the Company
all Records (whether furnished by the Company or prepared by Executive), and
Executive shall neither make nor retain any copies of any of such Records after
such termination.

                                       3
<PAGE>

                           (3) All inventions and other creations, whether or
not patentable or copyrightable, and all ideas, reports and other creative
works, including, without limitation, computer programs, manuals and related
materials, made or conceived in whole or in part by Executive while employed by
the Company and within six months thereafter, which relate in any manner
whatsoever to the business, existing or proposed, of the Company or any other
business or research or development effort in which the Company or any of its
subsidiaries or affiliates engages during Executive's employment by the Company
will be disclosed promptly by Executive to the Company and shall be the sole and
exclusive property of the Company. All copyrightable works created by Executive
and covered by this Section 3b(3) shall be deemed to be works for hire.
Executive shall cooperate with the Company in patenting or copyrighting all such
inventions, ideas, reports and other creative works, shall execute, acknowledge,
seal and deliver all documents tendered by the Company to evidence its ownership
thereof through the world, and shall cooperate with the Company obtaining,
defending and enforcing its rights therein.

                  c. CERTAIN CLAIMS UPON TERMINATION. Executive understands that
if within one year prior to the termination of Executive's employment with the
Company, Executive has either (i) committed an act of theft, dishonesty, gross
dereliction of duty, fraud, embezzlement, misappropriation, or breach of
fiduciary duty against the Company or any other act of comparable misconduct
against the Company; or (ii) breached any of his obligations under this
Agreement, then the Company shall have the right to purchase any or all shares
of Common Stock of the Company owned by Executive at the time of such
termination for a purchase price equal to the amount that Executive paid for
such shares, together with interest thereon at a rate of ten percent (10%) per
annum. If the Company desires to exercise such right, it shall notify Executive
within 60 days after the date of such termination and Executive shall tender the
shares being purchased by the Company at the time and place designated in such
notice from the Company upon receipt of the purchase price for such shares. If
Executive fails to tender such shares, the shares shall be deemed to be canceled
as of the date the Company tenders payment of the purchase price thereof.

                  d. ENFORCEABILITY. In the event of the breach of the covenants
contained in this Section 3, it is understood that damages will be difficult to
ascertain and the Company may petition a court of law or equity for injunctive
relief in addition to any other relief which the Company may have under the law,
this Agreement or any other agreement executed in connection herewith. In
connection with the bringing of any legal or equitable action for the
enforcement of this Agreement, the Company shall be entitled to recover, whether
the Company seeks equitable relief, and regardless of what relief is afforded,
such reasonable attorneys' fees and expenses as the Company may incur in
prosecution of the Company's claim for breach hereof.

                                       4
<PAGE>

         It is hereby agreed that the provisions of this Section 3 are separate
and independent from the other provisions of this Agreement, that these
provisions are specifically enforceable by the Company notwithstanding any claim
by Executive that the Company has violated or breached this Agreement or any
claim that Executive is entitled to any offset or compensation.

         To induce the Company to enter into this Agreement, Executive
represents and warrants to the Company that Section 3 of this Agreement is
enforceable by the Company in accordance with its terms.

         Company acknowledges and Executive agrees that legitimate disputes may
arise as a result of these provisions. Therefore, the Parties agree that
attempts to resolve these disputes concerning this section 3 will be subject to
Section 8: Dispute Resolution of this agreement.

         The parties hereto agree that to the extent that any provision or
portion of Section 3 of this Agreement shall be held, found or deemed to be
unreasonable, unlawful or unenforceable by a court of competent jurisdiction,
then any such provision or portion thereof shall be deemed to be modified to the
extent necessary in order that any such provision or portion thereof shall be
legally enforceable to the fullest extent permitted by applicable law; and the
parties hereto do further agree that any court of competent jurisdiction shall,
and the parties hereto do hereby expressly authorize, request and empower any
court of competent jurisdiction to, enforce any such provision or portion
thereof or to modify any such provision or portion thereof in order that any
such provision or portion thereof shall be enforced by such court to the fullest
extent permitted by applicable law.

         4. ADDITIONAL ACTIVITIES. Executive agrees that during the period of
his employment by the Company, he will not, without the Company's express
written consent, engage in any employment or business activity other than for
the Company. Executive may manage his own personal investments and participate
in professional, community, and public service activities, to the extent that
such activities do not interfere with the performance of his obligations to the
Company.

         Executive agrees that during the period of his employment by the
Company, without first obtaining the express written consent of the Company, he
will not: (a) own more than five percent (5%) of the issued and outstanding
stock in any publicly traded company and/or (b) have any financial interest in
any privately held company if such publicly traded or privately held company is
or becomes a competitor of the Company. Executive will have fifteen (15) days
following written notice from the Company that he is in breach of (a) or (b) in
which to cure such breach.

                                       5
<PAGE>

         5. TERMINATION OF EMPLOYMENT. Executive and the Company each
acknowledge that either Party has the right to terminate Executive's employment
with the Company at any time for any reason whatsoever, with or without cause or
advance notice, subject to the provisions below.

                  5.1. TERMINATION FOR CAUSE. The Company will have the right to
terminate Executive's employment with the Company at any time for "cause".
"Cause" for termination will mean only: (i) Executive has committed any material
act of embezzlement, fraud and/or is convicted of a felony; (ii) Executive
engages in unfair competition with the Company or willfully breaches his
obligations under this Agreement; (iii) Executive causes material damage to the
Company through intentional misconduct or gross neglect of the duties customary
to his office or (iv) Executive breaches his fiduciary duty to the Company. No
activity or inactivity covered by items (ii), (iii) or (iv) will be deemed to be
"cause" unless the company has notified Executive of such activity or inactivity
in writing and Executive has failed to cure the same within fifteen (15) days.

                  In the event Executive's employment is terminated at any time
with cause, he will not be entitled to severance pay, pay in lieu of notice or
any other such compensation, but he will be entitled to compensation, benefits
and un-reimbursed expenses accrued through the date of termination.

                  5.2. TERMINATION WITHOUT CAUSE. The Company will have the
right to terminate Executive's employment with the Company at any time without
cause. In the event Executive's employment is terminated at any time without
cause, the Company will pay Executive his severance in the form of a
continuation of the base salary in effect at time of termination, less standard
payroll deductions and withholdings, and insurance benefits for the remaining
term of this Agreement.

                  5.3. VOLUNTARY TERMINATION. Executive may voluntarily
terminate his employment with the Company at any time, after which no further
compensation will be paid to Executive. To permit the Company to make
arrangements to fill the vacancy created by Executive's departure, Executive
agrees to give the Company thirty (30) days advance notice of any intended
resignation. In the event Executive voluntarily terminates his employment, he
will not be entitled to severance pay, pay in lieu of notice or any other such
compensation, but he will be entitled to all compensation, benefits and
un-reimbursed expenses accrued through the date of termination.

         6. NOTICES. All notices, requests, consents and other communications
("Notice"), required or permitted to be given hereunder will be in writing and
will be deemed to have been duly given if personally delivered or delivered by
registered or certified mail (return receipt requested), or private overnight
mail (delivery confirmed by such service), to the following addresses, or to
such other address as either Party designates by notice in writing to the other
in accordance herein:

                                       6
<PAGE>

         IF TO THE COMPANY:
         ------------------

         1000 S. McCaslin Blvd.
         Suite 300
         Superior, CO 80027

         IF TO EXECUTIVE:
         ----------------
         At such address provided to the Company by him in writing

         7. GOVERNING LAW, PERSONAL JURISDICTION AND EXCLUSIVE FORUM. This
Agreement was entered into in the State of Colorado and the parties agree and
intend that it be construed and enforced in accordance with the laws of the
State of Colorado. Executive hereby expressly consents to the personal
jurisdiction of the state and federal courts located in the State of Colorado
for any lawsuit filed against Executive by the Company arising from or related
to this Agreement. Any controversy arising out of or relating to this Agreement
or the breach thereof, or any claim or action to enforce this Agreement or
portion thereof, or any controversy or claim requiring interpretation of this
Agreement must be brought in a forum located within the County of Denver State
of COLORADO. No such action may be brought in any forum outside the County of
Denver, State of Colorado. Any action brought in contravention of this paragraph
by one party is subject to dismissal at any time and at any stage of the
proceedings by the other, and no action taken by the other in defending, counter
claiming or appealing shall be construed as a waiver of this right to immediate
dismissal. A party bringing an action in contravention of this paragraph shall
be liable to the other party for the costs, expenses and attorney's fees
incurred in successfully dismissing the action or successfully transferring the
action to a forum located within the State of Colorado.

         8. DISPUTE RESOLUTION. Company and Executive agree that legal
proceedings should not necessarily be the first course of action should disputes
arise concerning elements of the Agreement. Accordingly, the Company and
Executive agree that if any disputes arise regarding this Agreement that are not
resolved through negotiation, the parties shall first submit such disputes to
non-binding mediation through a mutually agreed upon mediator or if such cannot
be agreed upon, each party will choose a mediator and both such mediators shall
choose a third mediator and all three mediators shall determine the dispute. If
either party is not satisfied with the decision of the mediator(s), the parties
will then submit such disputes to non-binding arbitration through the JAG office
in Denver, Colorado and if either party is not satisfied with the arbitration
decision, then such party may bring an action in Denver District Court, Denver,
Colorado which shall have exclusive jurisdiction regarding such dispute. The
prevailing party in either mediation, arbitration or in court shall have the
right to receive its attorney's fees and court costs regarding such action and
the award of such fees and costs will be binding upon all parties.

                                       7
<PAGE>

         8. GENERAL.

                  8.1. ENTIRE AGREEMENT. This Agreement sets forth the complete,
final and exclusive embodiment of the entire agreement between Executive and the
Company with respect to the subject matter hereof. This Agreement is entered
into without reliance upon any promise, warranty or representation, written or
oral, other than those expressly contained herein, and it supersedes any other
such promises, warranties, representations or agreements. This Agreement may not
be amended or modified except in a written instrument signed by Executive and a
duly authorized officer or director of the Company.

                  8.2. SEVERABILITY. If a court of competent jurisdiction
determines that any term or provision of this Agreement is invalid or
unenforceable, then the remaining terms and provisions will be unimpaired. Such
court will have the authority to modify or replace the invalid or unenforceable
term or provision with a valid and enforceable term or provision which most
accurately represents the Parties' intention with respect to the invalid or
unenforceable term or provision.

                  8.3. SUCCESSORS AND ASSIGNS. This Agreement will bind the
heirs, personal representatives, successors, assigns, executors and
administrators of each Party, and it will inure to the benefit of each Party,
and his or its heirs, successors and assigns. However, because of the unique and
personal nature of Executive's duties under this Agreement, Executive may not
delegate the performance of his duties under this Agreement.

                  8.4. HEADINGS. The section headings contained herein are for
reference purposes only and will in no way affect the meaning or interpretation
of this Agreement.

                  8.5. COUNTERPARTS AND FACSIMILE SIGNATURE. This Agreement may
be executed in two (2) counterparts, each of which will be deemed an original,
all of which together will constitute one and the same instrument. A facsimile
signature shall be deemed an original signature for all purposes.

                           [SIGNATURE PAGE TO FOLLOW]

                                       8
<PAGE>

IN WITNESS WHEREOF, the Parties have duly authorized and caused this Agreement
to be executed as follows:

                                                    ACUNETX, INC.

EXECUTIVE                                           By: Terry Knapp

By:/s/ Ronald A. Waldorf

                                                    Name(print): Terry Knapp

Name(print):Ronald A. Waldorf                       Title: President

                                       9<PAGE>

EXHIBIT 10.3

                               LICENSING AGREEMENT

         THIS LICENSING AGREEMENT (the "Agreement") is entered into effective
November 15, 2004, between ORTHONETX, INC., a Nevada corporation, and TERRY
KNAPP, M.D. ("Knapp"). OrthoNetx, Inc. and its subsidiary corporations are
hereinafter referred to as "ORTHONETX."

                              EXPLANATORY STATEMENT
                              ---------------------

         A. ORTHONETX is a medical device company that is currently developing
and marketing certain distraction osteogenesis devices and plans to create and
incorporate an Interactive Bone Information System ("IBIS") and an Interactive
Device Information System ("IDIS") (IBIS and IDIS collectively, "IBIS/IDIS") for
use in conjunction with its medical devices.

         B. Knapp has developed certain proprietary technology included in U.S.
Patent 6,278,999 entitled "Information Management System for Personal Health
Digitizers" (the "Knapp Patent") for an information management system that can
be utilized in ORTHONETX's IBIS/IDIS.

         C. Knapp desires to license its Knapp Patent to ORTHONETX for
incorporation in ORTHONETX's IBIS/IDIS and for ORTHONETX's use of the Knapp
Patent in the field of medical device implants as addressed by the IBISIIDIS
platform.

         NOW THEREFORE, in consideration of the foregoing Explanatory Statement,
which is made a substantive part of this Agreement and the promises, covenants
and representations made herein and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, it is agreed as
follows:

                                    ARTICLE 1
                                      TERM

         1.1 TERM. This Agreement shall become effective upon execution and
shall continue in full force and effect for five (5) years, unless sooner
terminated in accordance with its terms. This Agreement shall be renewed
automatically for additional five (5) year terms at the expiration of each
preceding term unless ORTHONETX notifies Knapp, in writing, within thirty (30)
days prior to the renewal date, that it elects not to renew.

         1.2 PRIOR TERMINATION. Anything contained in Section 1.1 above to the
contrary notwithstanding, this Agreement may be terminated and the obligations
of the parties hereunder shall thereupon cease, upon the occurrence of the
following:

                  (a) Knapp may elect to terminate this Agreement by providing
ORTHONETX with ninety (90) days notice in writing in the event ORTHONETX fails
to substantially perform its duties hereunder. ORTHONETX shall have the right to
cure such non-performance within ninety (90) days of such Default Notice and if
ORTHONETX cures such non-performance within the ninety (90) day period, this
Agreement shall remain in full force and effect.

<PAGE>

                  (b) Knapp may also elect to terminate this Agreement by
providing ORTHONETX with ninety (90) days notice in writing if ORTHONETX,
through its board of directors, does not utilize the Knapp Patent in conjunction
with any of its medical devices or fails to sublease the Knapp Patent in
accordance with this Agreement within two (2) years of the date of this
Agreement.

                                    ARTICLE 2
                            LICENSE OF ICNAPP PATENT

         2.1 LICENSING. In consideration of the payments to be made in
accordance with this Agreement, Knapp hereby grants to ORTHONETX an exclusive,
transferable (with the right to sublicense) license to use the Knapp Patent in
relation to the development, manufacturing, marketing and servicing of medical
device implants as addressed by the IBIS/IDIS platform in the United States and
worldwide. The license rights shall include the right to use and further develop
technology included in the Knapp Patent for use in its IBIS/IDIS platform.

         2.2 LICENSE RESTRICTIONS. Except as otherwise expressly authorized in
writing by Knapp, ORTHONETX shall not use the Knapp Patent other than in
accordance with the provisions of this Agreement.

         2.3 DURATION. This Agreement and the licenses hereby granted shall
commence on the date of counter-signature by Knapp of this Agreement and shall
continue in force for the term as set forth in Article 1.

         2.4 OWNERSHIP OF THE KNAPP PATENT.

                  (a) KNAPP PATENT OWNER. Knapp is the owner of the Knapp
Patent. Knapp is not aware at the date hereof that the Knapp Patent or the use
of it in relation to the field of medical device implants as addressed by the
IBISIIDIS platform infringes the rights of any third party but gives no warranty
in relation thereto, nor as to the validity of any applications.

                  (b) REPRESENTATIONS AS TO KNAPP PATENT. Knapp represents that
the Knapp Patent is a valid patent as filed and registered with the U.S. Patent
Office.

                  (c) NO WARRANTY. THE KNAPP PATENT IS PROVIDED TO ORTHONETX "AS
IS" AND WITHOUT WARRANTY OF ANY TYPE OR KIND. KNAPP HEREBY DISCLAIMS ANY AND ALL
WARRANTIES, WHETHER STATUTORY, EXPRESS, OR IMPLIED, INCLUDING WITHOUT
LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY FOR A PARTICULAR PURPOSE,
AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY RIGHTS EXCEPT THAT KNAPP
WARRANTS ONLY THAT THE KNAPP PATENT IS A VALID PATENT AS FILED AND REGISTERED
WITH THE U.S. PATENT OFFICE AND THAT HE IS NOT AWARE AT THE DATE HEREOF OF ANY
THIRD PARTY CLAIM THAT THE KNAPP PATENT OR THE USE OF IT ON OR IN RELATION TO
MEDICAL IMPLANT DEVICES INFRINGES THE RIGHTS OF SUCH THIRD PARTY OR PARTIES.

                                       2
<PAGE>

                  (d) NO CONTEST TO KNAPP PATENT. During the term of this
Agreement and thereafter, ORTHONETX undertakes not to do or permit to be done
any act which would or might jeopardize or invalidate the Knapp Patent, nor any
application and/or registration thereof, nor do any act which might prejudice
the right of Knapp to the Knapp Patent. Furthermore, ORTHONETX will not object
to or otherwise contest Knapp's exclusive right, title and interest in and to,
or the validity of, the Knapp Patent, subject to this Agreement.

                  (E) ORTHONETX ASSISTANCE IN MAINTAINING KNAPP PATENT ORTHONETX
shall on request give to Knapp or its authorized representative any information
as to its use of the Knapp Patent which Knapp may reasonably require.

         2.5 INFRINGEMENTS.

                  (a) INFRINGEMENTS OF THE KNAPP PATENT. ORTHONETX shall
immediately notify Knapp in writing if ORTHONETX becomes aware of any
unauthorized use, or proposed unauthorized use, by any person of a possible
infringement of the Knapp Patent, and grants ORTHONETX the right to take such
action, at ORTHONETX's own expense, and by attorneys of ORTHONETX's choice, as
ORTHONETX in its sole discretion may deem advisable, including the right to sue
for infringement of ORTHONETX's license rights pursuant to this Agreement. Any
such action taken by ORTHONETX may be taken in the name of Knapp or ORTHONETX,
as ORTHONETX deems appropriate. The monetary proceeds from any such action,
claim or settlement arising from any such action, will belong exclusively to
ORTHONETX after the deduction of all of Knapp's own costs incurred as a result
of such proceedings, if any.

                  (b) KNAPP PATENT INFRINGEMENT. If either party or their
subsidiaries receive notice (the "Infringement Notice") from any third party
alleging that the Knapp Patent infringes upon any third party's patent or
technology, then such party receiving the Infringement Notice shall immediately
notify the other party and all parties hereto and their subsidiaries will
mutually decide what action shall be taken in response to the claim of
infringement.

                  (c) COOPERATION. Each party shall, at the request of the other
party, cooperate with each other in any action, claim or proceedings brought or
threatened in respect of the Knapp Patent as licensed to ORTHONETX pursuant to
this Agreement.

         2.6 FEES. AS full consideration for its license rights pursuant to this
Agreement, ORTHONETX agrees to the following:

                   (a) ORTHONETX, beginning two years from the date of this
agreement, will pay Knapp a royalty of two percent (2%) of the net income, as
determined by generally accepted accounting principals applied by ORTHONETX's
certified public accountants, received by ORTHONETX from the sale of any of its
devices that use the Knapp Patent in its medical devices as addressed by the
ORTHONETX's IDIS/IBIS system.

                                       3
<PAGE>

                  (b) If ORTHONETX creates a business on sublicensing, servicing
or selling IBISIIDIS utilizing the Knapp Patent to other medical device
manufacturers, ORTHONETX will pay Knapp a royalty of two percent (2%) of the net
income, as determined by generally accepted accounting principals applied by
ORTHONETX's certified public accountants, received by ORTHONETX based on such
business activities.

         2.7 SURVIVAL OF RIGHTS AND OBLIGATIONS UPON TERMINATION. All provisions
of this Agreement which in order to give effect to their meaning need to survive
its termination shall remain in full force and effect thereafter.

         2.8 CONFIDENTIALITY.

                  (a) CONFIDENTIAL INFORMATION. ORTHONETX shall, except where a
provision of the Agreement provides otherwise, maintain in confidence all
information disclosed to it under or in relation to this Agreement by Knapp,
which is in writing marked "confidential" or, if oral or visual, is identified
as confidential at the time of disclosure and reduced to writing marked
"confidential" and sent to ORTHONETX within thirty (30) days thereafter, and
shall not use any such information except for the purposes of this Agreement.
ORTHONETX's obligations under this subclause shall be limited to taking such
steps as it ordinarily takes to preserve the most important of its own
confidential information. Notwithstanding the foregoing, ORTHONETX may disclose
the basic terms of this Agreement in any private placement offering of its
securities or any filing with the Securities and Exchange Commission (the "SEC")
and may also include this Agreement as an exhibit to any filings with the SEC if
required by applicable law or regulations.

                  (b) NON-CONFIDENTIAL INFORMATION. The obligations of
non-disclosure and non-use set out above shall not apply to any item of
information which: (a) is in the public domain at any time (but without
prejudice to any person's rights of action against another person who wrongfully
causes or permits such information to be in the public domain); (b) was
rightfully in a person's possession without obligation of confidence prior to
its disclosure pursuant to this Agreement, or is subsequently independently
developed by that person by employees having no access to the information
disclosed hereunder; (c) is subsequently rightfully obtained without obligation
of confidence by a person from a source other than ORTHONETX as evidenced by
written records, or (d) is required to be disclosed by order of any court of
competent jurisdiction or to enable the Knapp Patent or any license thereunder
to be validly registered, PROVIDED that no right or interest under any license,
patent, or otherwise shall be acquired by the recipient of any information by
virtue of the application of this section.

                  (c) SURVIVAL OF CONFIDENTIALITY OBLIGATIONS. The obligations
of non-disclosure and the limitations on use, set out above, shall survive
termination of this Agreement.

         2.9 CONTINGENCY. This Agreement and the obligations of the parties
herein are expressly subject to and contingent upon the completion of the
minimum funding of the ORTHONETX financing pursuant to the ORTHONETX Private
Placement Memorandum of November, 2004. If such financing or alternative is not
completed within four (4) months of the date of this Agreement, this Agreement
shall be null and void.

                                       4
<PAGE>

                                    ARTICLE 3
                               GENERAL CONDITIONS

         3.1 ADDITIONAL ACT OR DOCUMENTATION. Knapp and ORTHONETX agree to make,
execute, and deliver such additional documents and instruments and take such
actions as may be necessary or appropriate to carry out the full intent and
purpose of this Agreement.

         3.2 NOTICES. Any notices that may be required under this Agreement
shall be in writing, shall be effective on the earlier of the date when received
or the third day following mailing, and shall be given by personal service, or
by certified or registered mail, return receipt requested, to the addresses set
forth below, or to such other addresses as may be specified in writing to all
parties hereto.

         3.3 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective successors in
interest, but in no event shall any party be relieved of its obligations
hereunder without the express written consent of each other party except as
expressly provided herein.

         3.4 SEVERABILITY. To the full extent possible, each provision of this
Agreement shall be interpreted in such fashion as to be effective and valid
under applicable law. If any provision of this Agreement is declared void or
unenforceable with respect to particular circumstances, such provision shall
remain in full force and effect in all other circumstances. If any provision of
this Agreement is declared void or unenforceable, such provision shall be deemed
severed from this Agreement, which shall otherwise remain in full force and
effect.

         3.5 COUNTERPARTS AND FACSIMILE SIGNATURE. This Agreement may be
executed in any number of counterparts, all such counterparts shall be deemed to
constitute one and the same instrument, and each of the executed counterparts
shall be deemed an original hereof. A facsimile signature shall be deemed an
original for all purposes.

         3.6 GOVERNING LAW. This Agreement shall be deemed to be made under, and
shall be construed in accordance with and shall be governed by, the internal
laws of the United States of America and the State if Colorado. Suit to enforce
any provision of this Agreement or to obtain any remedy with respect hereto
shall be brought in District Court for the County of Arapahoe, or Federal
District Court in Denver, Colorado, and each party hereto expressly and
irrevocably consents to the jurisdiction of said court.

         3.7 ENTIRE AGREEMENT; CAPTIONS. THIS Agreement and the agreements
referenced herein contain the entire agreement and understanding of the parties
with respect to the subject matter hereof, and all prior agreements and
understandings of the parties with respect to such subject matter are hereby
superseded. No representations, promises, agreements, or understandings not
contained in this Agreement regarding the subject matter hereof shall be of any
force or effect unless in writing, executed by the party to be bound and dated
on or subsequent to the date hereof. Captions and headings are for convenience
only and shall not alter any provision or be used in construing this Agreement.

                                       5
<PAGE>

         3.8 TIME. Time is of the essence of this Agreement and each and every
provision hereof Any extension of time granted for the performance of any duty
under this Agreement shall not be considered an extension of time for the
performance of any other duty under this Agreement.

         3.9 GENDER AND NUMBER. Wherever from the context it appears
appropriate, each item stated in the singular shall include the plural and vice
versa, and the masculine, feminine, or neuter form shall include the masculine,
feminine, and neuter forms.

         3.10 MODIFICATIONS AND WAIVERS. No change, modification, or waiver of
any provision of this Agreement shall be valid or binding unless it is in
writing dated after the date hereof and signed by the parties intended to be
bound. No waiver of any breach, term or condition of this Agreement by either
party shall constitute a subsequent waiver of the same or any other breach,
term, or condition or a continuing waiver after demand for strict compliance.

         3.11 ADVISEMENT OF REPRESENTATION. The law firm of Michael J. Tauger
has assisted in drafting this Agreement and has done so at the request of its
client, ORTHONETX (the "Client"). Michael J. Tauger, Esq. represents only its
Client and no other person or entity in this transaction.

         3.12 NOTICES. For all purposes of this Agreement, unless changed by
written notice, the mailing addresses of the parties shall be:

ORTHONETX's Notice Address:               Knapp's Notice Address:

2075 S. University Blvd., #212            7451 N. 63rd Street
Denver, CO 80210-4300                     Niwot, CO 80503

         This Agreement is entered into effective the date first written above.

ORTHONETX:                                                 Knapp:

ORTHONETX, Inc.

By: /s/ Randolph Robinson                                  /s/ Terry Knapp
    -----------------------------------                    ---------------------
    Randolph Robinson, M.D., D.D.S.                        Terry Knapp, Chairman

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]